alpha-synuclein – Discover Pharma

Welcome to Discover Pharma! Today is : November 14, 2026

alpha-synuclein

Central Nervous System,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
Amyl Therapeutics raises €8.25M to advance pan-amyloid neurodegenerative disease platform
Amyl Therapeutics has raised €8.25m to generate preclinical data for [...]

September 14, 2026
Central Nervous System,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune gets FDA Fast Track for Parkinson’s immunotherapy ACI-7104
AC Immune has received FDA Fast Track designation and IND [...]

August 12, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
AC Immune advances Parkinson’s and Alzheimer’s pipeline with key clinical milestones ahead
AC Immune has outlined a series of clinical milestones expected [...]

August 5, 2026
Central Nervous System,Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development,Therapeutic Areas
ABLi reports biomarker changes supporting disease-modifying potential of Parkinson’s drug
ABLi Therapeutics has reported coordinated changes across 11 biomarkers linked [...]

August 4, 2026
Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas
AC Immune interim Phase 2 data suggest ACI-7104.056 may slow Parkinson’s disease progression
AC Immune SA has reported positive interim results from [...]

May 5, 2026

This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.

OK